58 results about "Neoplasm" patented technology

The present application discloses substituted polycyclic heterocycles compound of Formula (I), pharmaceutically acceptable salt and / or solvate and pharmaceutical compositions thereof useful in the treatment of proliferative disease or condition characterized by a dysregulation of the RAS-ERK pathway such as neoplasm disease or disorder, inflammatory disease or immune system disorder.

The invention relates to a Kluyveromyces marxianus strain with high protein yield and application of the Kluyveromyces marxianus strain, which is characterized in that the Kluyveromyces marxianus strain is firstly cultured on a slant, then is transferred into a seed culture medium for seed preparation, and then is inoculated into a fermentation tank, and yeast protein is obtained by adopting index feeding; the bacterial strain is a dominant mutant strain Kluyveromyces marxianus YWX-1, the protein content in a dry thallus reaches 55% or above and is increased by 26% or above compared with that of an original bacterial strain, the bacterial strain can be used for production of single-cell protein, the essential amino acid index (EAAI) value in the protein reaches 1.2, and the bacterial strain is rich in arginine, threonine and lysine and can be applied to production of single-cell protein. These amino acids play a key role in immune regulation, intestinal mucosal barrier function and muscle protein synthesis of young animals. The YWX-1 kluyveromyces marxianus strain has a wide application prospect in the production of neoplasm protein.

Therapeutic compositions comprising chitosan-derived compositions are useful agents when administered in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.

This disclosure relates to a method for detecting colorectal cancer. The method comprises determining whether an advanced neoplasm is present in a first screening time period and upon determining that an advanced neoplasm is present in the first screening time period, performing colonoscopy in a second screening time period, after the first screening time period, to detect colorectal cancer. There is further provided a method for stratification of a subject comprising upon detection of an advanced neoplasm in a first screening time period, stratifying the subject into a high risk stratification for developing colorectal cancer in a second screening time period. There is further provided a computer implemented method for calculating a risk score for developing colorectal cancer comprising determining patient data; applying a trained machine learning model to the patient data to determine the risk score; and outputting the risk score.

Processes and materials to detect neoplasms from a biopsy are described. Processes and materials to build a sequencing library are described. Processes and material to perform targeted sequencing are described. Processes and materials to mitigate confounding sources are described. Cell-free nucleic acids can be sequenced and the sequencing result can be utilized to detect sequences derived from a neoplasm.

The present disclosure describes the use of an anti-insulin receptor antibody to treat neoplasms and / or tumor-associated hyperinsulinism and resulting hypoglycemia caused by benign or malignant neoplastic production of insulin and / or other effector substances (e.g., IGF-2 or its variants) that interact with the INSR and thus result in insulin-like action.

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases in a subject, wherein the proliferative diseases include cancer, benign neoplasm, angiogenesis, inflammatory disease, autoinflammatory disease, and autoimmune disease, and the cancer includes leukemia, melanoma, multiple myeloma. Treatment of a subject having a proliferative disease with the compounds or compositions of the present invention can inhibit abnormal activity of cyclin-dependent kinase 7, thus inducing apoptosis and / or inhibiting transcription in the subject.

Crystalline forms, including salts and polymorphs, of a compound useful in the treatment of tetracycline compound-responsive states are provided herein. The crystalline compounds are useful for the treatment or prevention of conditions and disorders such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds in general.

Processes and materials to detect cancer, transplant rejection, or fetal genetic abnormalities from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences indicative of a neoplasm, transplant rejection, or fetal genetic abnormality. Detection of somatic variants occurring in phase and / or insertions and deletions (indels) can indicate the presence of cancer, transplant rejection, or fetal genetic abnormalities in a diagnostic scan, and a clinical intervention can be performed.

The present disclosure relates to the use of compound (I) and any of its salts for the treatment of a neoplasm characterized by high expression of toll-like receptor 4 (TLR4) in the tumor or its microenvironment, associated with at least one of the pathophysiological complications including immunosuppression, angiogenesis, fibrosis, or metastasis.

The present invention relates to systems and methods for classification of cancer from gene expression input data. The method including: receiving a training dataset including nucleic acid data points from one or more samples; identifying classes in the training dataset including performing recursive clustering by, at each successive iteration, performing a search to identify clusters based on similarity, wherein each class of the classes is associated with a tumor; training a machine learning model to associate the nucleic acid data points of the training dataset with the identified classes; receiving the gene expression input data for classification; classifying, using the trained machine learning model, the gene expression input data as one or more of the identified classes; and outputting the classification of the gene expression input data.

The present disclosure provides a method for the treatment of neoplastic disease in a mammalian subject the method comprising the administration of an IL-10 agent in combination with the administration of at least one modulator of at least one immune checkpoint pathway. The present disclosure further provides a method for the treatment of neoplastic disease wherein the neoplasm has a low or intermediate tumor mutation burden, low or intermediate level of expression of the immune checkpoint molecule, or metastatic neoplastic disease.

Disclosed are methods of treatment, compositions and kits comprising endocannabinoid receptor (ECR) antagonist and an mTOR inhibitor for treating neoplasm in a subject in need thereof, and reducing drug resistance to standard treatment.

The present invention relates to novel and stable preparations of bacterial extracts that exhibit considerably greater stability over time, to new methods of preparing them, to pharmaceutical formulations based on these new stabilized bacterial extracts, as well as to new routes of administration and delivery devices for the treatment and / or prevention of acute and chronic immunological disorders resulting from infections, inflammation, neoplasms, or dysbiosis.

Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as gastric cancer.

The invention relates to cannabidiol-based (CBD) formulations, and to their use in treating, preventing or alleviating pain, inflammation, an autoimmune disease, a neurological disease, neoplasm, or nausea in a subject. The invention also concerns low-dose CBD compositions, and extends to their use in methods of treatment.

The present invention relates to novel compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, a medicinal use thereof, and a method for preparing the same. The novel compounds according to the present invention, stereoisomers thereof or pharmaceutically acceptable salts thereof have the histone deacetylase 6 (HDAC6) inhibitory activity, and are effective in preventing or treating HDAC6-related diseases, comprising infectious diseases; neoplasm; endocrinopathy; nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; eye and ocular adnexal diseases; circulatory diseases; respiratory diseases; digestive diseases; skin and subcutaneous tissue diseases; musculoskeletal system and connective tissue diseases; and teratosis or deformities, or chromosomal aberration.

The present disclosure provides T cell receptors (TCRs) that bind to COL6A3 and their use in medical treatment or prophylaxis, for example the treatment of COL6A3-expressing neoplasms or cancers. The present disclosure also provides nucleic acids and expression vectors that encode the TCRs.

The present invention relates to pharmaceutical agents useful for therapy and / or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin / MLL protein / protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproiiferative neoplasms (MPN); and diabetes.

Provided herein are methods for treating a brachyury-associated cancer or neoplasm, e.g., chordoma, with a type I interferon in a subject in need thereof. The methods further include treating the brachyury-associated cancer or neoplasm with interferon alpha or interferon beta by injection of interferon protein into a subject in need thereof, wherein the interferon can be an interferon polypeptide or an interferon nucleic acid formulated for expression.

This disclosure relates to antibodies and derivatives that bind the full-length isoform of aspartate beta-hydroxylase (ASPH) and uses thereof. The antibodies and derivatives are useful in compositions and methods for detecting and / or treating a malignant neoplasm in a subject and for predicting subsequent complications of untreated progression of the malignant neoplasm in the subject.

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopologues, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and / or preventing diseases (e.g., proliferative diseases (e.g., cancers and benign neoplasms), inflammatory diseases (e.g., rheumatoid arthritis), and vascular diseases (e.g., atherosclerosis) in a subject. Provided are methods of inhibiting a INK (e.g., JNK1, JNK2, or JNK3) in a subject.

The present invention provides novel hydroquinone derivatives of formula (I), processes of preparation, as well as pharmaceutical compositions and methods of treating and / or preventing e.g. autoimmune, immunological, rheumatology, vascular disorders, ophthalmologic disorders, fibrotic disorders, metabolic and gastrointestinal disorders, neuroinflammatory and neurodegenerative diseases, neoplasms and cancer associated disorders, hormone related diseases and immunological disorders resulting from viral and bacterial infectious diseases and complications thereof. wherein R 1 is COOR 4, (CH 2 ) n COOR 4, SO 3 H, (CH 2 ) n SO 3 H or CONH-R 10; one of R 2 and R 3 is H and the other is R 5.

Disclosed are compositions comprising delta-tocotrienol and methods for using the same in the prevention of cancer progression. The methods comprise of reducing, inhibiting, decreasing, and / or preventing the progression of a neoplasm to a cancer (including, but not limited to lung cancer, ovarian cancer, breast cancer, rectal cancer, pancreatic, colon cancer, or intraductal papillary mucinous neoplasm (IPMN) to pancreatic ductal adenocarcinoma) in a subject comprising administering to a subject a therapeutically effective amount of a composition comprising delta-tocotrienol (d-T3).

The skin benign neoplasm removing device for the dermatology department comprises a bracket and a removing assembly, the removing assembly comprises a rotating seat rotationally connected with one side of the bracket, an orientation rod and a pair of clamping rods are arranged on the rotating seat, an end plate is slidably clamped between the two clamping rods, and the two ends of the end plate are connected with a fixing seat and an orientation block correspondingly; the orienting rod penetrates through the inner side of the orienting block; a connecting cylinder is arranged at the top end of the fixed seat; the removing assembly can remove benign skin neoplasm on the skin surface of a patient, the device combines the functions of cutting and scraping the neoplasm, and compared with mainstream laser treatment, physical scraping treatment cannot cause heat damage to peripheral tissues, so that compared with laser treatment, the physical scraping treatment has the advantages that the treatment efficiency is greatly improved, and the treatment cost is reduced. And the probability of scars left after complete healing is lower, so that the removal effect of the device is improved.

Methods and uses of immunoconjugates that bind to CD123 (e.g., pivekimab sunirine) in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) are provided. Such immunoconjugates can be used, for example, to prepare patients with BPDCN for hematopoietic stem cell transplant, to achieve bone marrow remission in BPDCN patients with bone marrow involvement, and to achieve long-lasting complete remissions in patients with BPDCN as a result of a short treatment period.

Described are devices, systems, and methods for controlled delivery of therapeutic and / or diagnostic agent(s) in a tissue in a subject. In particular, provided are carrier devices in which the agent(s) may be enclosed. One or more carrier devices may be injected or implanted at target loci in a tissue, such as in a malignant neoplasm. The agent(s) may diffuse from the carrier devices in a predetermined and controlled manner. Further provided are methods for developing optimized parameters for intraparenchymal placement of carrier devices and diffusion of the agent(s), to achieve an optimized therapeutic exposure in the target tissue. Further provided are devices and systems for intraparenchymally placing carrier devices at desired loci in a tissue.

A computer-implemented method for detecting tumor subclones may include receiving one or more digital images into a digital storage device, the one or more digital images including images of a tumor of a patient, detecting one or more neoplasms in the one or more received digital images for each patient, extracting one or more visual features from each detected neoplasm, determining a hierarchy dendrogram based on the detected one or more neoplasms and the extracted one or more visual features for each detected neoplasm, determining one or more leaf nodes based on the determined hierarchy dendrogram, and determining whether there are two or more neoplasms among the detected one or more neoplasms that originated independently.

Processes and materials to detect neoplasms from a biopsy are described. Processes and materials to build a sequencing library are described. Processes and material to perform targeted sequencing are described. Processes and materials to mitigate confounding sources are described. Cell-free nucleic acids can be sequenced and the sequencing result can be utilized to detect sequences derived from a neoplasm.

Methods and uses of immunoconjugates that bind to CD123 (e.g., pivekimab sunirine) in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) are provided. Such immunoconjugates can be used, for example, to prepare patients with BPDCN for hematopoietic stem cell transplant, to achieve bone marrow remission in BPDCN patients with bone marrow involvement, and to achieve long-lasting complete remissions in patients with BPDCN as a result of a short treatment period.